• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Alpine Immune Sciences Inc.

    5/20/24 9:37:11 AM ET
    $ALPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALPN alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-37449
    Issuer: ALPINE IMMUNE SCIENCES, INC.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 201 Elliott Avenue West
    Suite 230
    Seattle WASHINGTON 98119
    Telephone number: (206) 788-4545
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    common stock
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2024-05-20 By Tara Petta AVP
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ALPN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALPN

    DatePrice TargetRatingAnalyst
    4/9/2024$55.00Buy
    Guggenheim
    2/15/2024$44.00Outperform
    Wolfe Research
    10/18/2023$18.00Buy
    Berenberg
    10/17/2023$18.00Buy
    Berenberg
    10/5/2023$19.00Outperform
    RBC Capital Mkts
    6/26/2023$14.00Outperform
    Oppenheimer
    1/19/2023$17.00Overweight
    Morgan Stanley
    11/21/2022$15.00Outperform
    SVB Leerink
    More analyst ratings

    $ALPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Peetz Christopher returned 1,900 shares to the company (SEC Form 4)

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      5/20/24 8:14:39 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Hernday Natasha

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      5/20/24 8:13:47 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Drappa Jorn

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      5/20/24 8:12:51 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALPN
    SEC Filings

    See more
    • SEC Form 15-12G filed by Alpine Immune Sciences Inc.

      15-12G - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)

      5/30/24 9:12:26 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Alpine Immune Sciences Inc.

      EFFECT - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)

      5/24/24 12:15:07 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Alpine Immune Sciences Inc.

      EFFECT - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)

      5/24/24 12:15:33 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALPN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Decheng Capital Global Healthcare Fund (Master), Lp bought $4,687,500 worth of shares (375,000 units at $12.50) (SEC Form 4)

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      11/14/23 5:36:42 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Alpine Immune Sciences with a new price target

      Guggenheim initiated coverage of Alpine Immune Sciences with a rating of Buy and set a new price target of $55.00

      4/9/24 7:38:17 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Alpine Immune Sciences with a new price target

      Wolfe Research initiated coverage of Alpine Immune Sciences with a rating of Outperform and set a new price target of $44.00

      2/15/24 6:19:18 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berenberg initiated coverage on Alpine Immune Sciences with a new price target

      Berenberg initiated coverage of Alpine Immune Sciences with a rating of Buy and set a new price target of $18.00

      10/18/23 7:51:16 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALPN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Frazier Life Sciences Appoints Biotech Innovators Mitchell H. Gold and Stanford L. Peng as Venture Partners

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointments of Mitchell H. Gold, M.D., and Stanford L. Peng, M.D., Ph.D., as Venture Partners. "We believe Mitch and Stanford bring exceptional leadership and experience that will elevate our ability to create and nurture breakthrough biopharmaceutical companies," said Jamie Topper, M.D., Ph.D., Managing Partner at FLS. "Mitch's history of building transformative companies, his relentless pursuit of scientific excellence and his proven ability to identify transformative scientific and investment opportunities make him a valuable addition to our team. Similarly, Stanford's p

      1/9/25 8:00:00 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors

      FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades of industry leadership experience, including early- and late-stage therapeutic development and commercialization. "I am delighted to welcome Mitch and Angie to the team. They are industry leaders with a proven track record of success in building both public and private biopharma companies. As Attovia looks toward our next stage of growth and drives our mission of bringing forward first-in-c

      7/9/24 7:30:00 AM ET
      $ALPN
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Reports First Quarter 2024 Financial Results

      Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024. On April 10, 2024, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Alpine announced that the companies had entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share in cash. The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close in the second quarter of 2024. First Quarter 2024 Financial Results Cash Position and Runway: As of March

      5/9/24 4:00:00 PM ET
      $ALPN
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care